The invention provides new pyrazine derivatives of formula (I):

##STR00001##

or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

The invention provides new pyrazine derivatives of formula (I):

##STR00001##

or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

The invention provides new heterocyclic compounds having the general formula (I)

##STR00001##

wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The invention provides new heterocyclic compounds having the general formula (I)

##STR00001##

wherein A, L, X, m, n, R.sup.1 and R.sup.2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

A compound represented by the following formula (A1) (X.sub.1 is O or S; two or more of Y.sub.1, Y.sub.2, and Y.sub.3 are N; and Ar.sub.1 is an aryl group including 6 to 50 ring carbon atoms, comprising a benzene ring having at least substituent Ar.sub.2 at the ortho-position; Ar.sub.2 is an aryl group; and Ar.sub.3 is a predetermined group).

##STR00001##

A compound represented by the following formula (A1) (X.sub.1 is O or S; two or more of Y.sub.1, Y.sub.2, and Y.sub.3 are N; and Ar.sub.1 is an aryl group including 6 to 50 ring carbon atoms, comprising a benzene ring having at least substituent Ar.sub.2 at the ortho-position; Ar.sub.2 is an aryl group; and Ar.sub.3 is a predetermined group).

##STR00001##

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.